Does the media prefer RCUS or BBIO?

In the previous week, BridgeBio Pharma had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for BridgeBio Pharma and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.05 beat BridgeBio Pharma's score of 0.90 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is EXEL or RCUS more profitable?

Exelixis has a net margin of 35.33% compared to Arcus Biosciences' net margin of -393.16%. Exelixis' return on equity of 42.17% beat Arcus Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Arcus Biosciences -393.16% -89.54% -45.61%

Does the media favor EXEL or RCUS?

In the previous week, Exelixis had 24 more articles in the media than Arcus Biosciences. MarketBeat recorded 28 mentions for Exelixis and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.05 beat Exelixis' score of 0.54 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 12 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RCUS or SMMT?

In the previous week, Summit Therapeutics had 5 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for Summit Therapeutics and 4 mentions for Arcus Biosciences. Summit Therapeutics' average media sentiment score of 1.19 beat Arcus Biosciences' score of 1.05 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RCUS or BMRN?

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Arcus Biosciences. MarketBeat recorded 21 mentions for BioMarin Pharmaceutical and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.05 beat BioMarin Pharmaceutical's score of 0.79 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 8 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or RCUS?

In the previous week, Halozyme Therapeutics had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.05 beat Halozyme Therapeutics' score of 1.02 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcus Biosciences (RCUS) Competitors

$24.62 -1.53 (-5.84%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$24.41 -0.22 (-0.89%)

As of 09/11/2026 08:00 PM Eastern

Compare

RCUS vs. BBIO, EXEL, SMMT, BMRN, and HALO

Should you buy Arcus Biosciences stock or one of its competitors? Arcus Biosciences's main competitors and comparable companies include BridgeBio Pharma (BBIO), Exelixis (EXEL), Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arcus Biosciences compare to BridgeBio Pharma?

Arcus Biosciences (NYSE:RCUS) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

In the previous week, BridgeBio Pharma had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for BridgeBio Pharma and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.05 beat BridgeBio Pharma's score of 0.90 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences presently has a consensus price target of $38.30, suggesting a potential upside of 55.54%. BridgeBio Pharma has a consensus price target of $102.61, suggesting a potential upside of 41.65%. Given Arcus Biosciences' higher probable upside, research analysts plainly believe Arcus Biosciences is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arcus Biosciences has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

BridgeBio Pharma has a net margin of -97.03% compared to Arcus Biosciences' net margin of -393.16%. BridgeBio Pharma's return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Arcus Biosciences has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.69	-$353M	-$3.90	N/A
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A

Summary

BridgeBio Pharma beats Arcus Biosciences on 11 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Exelixis currently has a consensus price target of $50.07, suggesting a potential downside of 10.79%. Arcus Biosciences has a consensus price target of $38.30, suggesting a potential upside of 55.54%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

85.3% of Exelixis shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Exelixis has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.71	$782.57M	$3.18	17.65
Arcus Biosciences	$247M	12.69	-$353M	-$3.90	N/A

Exelixis has a net margin of 35.33% compared to Arcus Biosciences' net margin of -393.16%. Exelixis' return on equity of 42.17% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

In the previous week, Exelixis had 24 more articles in the media than Arcus Biosciences. MarketBeat recorded 28 mentions for Exelixis and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.05 beat Exelixis' score of 0.54 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	12 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Summary

Exelixis beats Arcus Biosciences on 9 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Summit Therapeutics?

Arcus Biosciences (NYSE:RCUS) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Arcus Biosciences has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.69	-$353M	-$3.90	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Arcus Biosciences presently has a consensus target price of $38.30, indicating a potential upside of 55.54%. Summit Therapeutics has a consensus target price of $25.91, indicating a potential upside of 47.63%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcus Biosciences is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

In the previous week, Summit Therapeutics had 5 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for Summit Therapeutics and 4 mentions for Arcus Biosciences. Summit Therapeutics' average media sentiment score of 1.19 beat Arcus Biosciences' score of 1.05 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Arcus Biosciences' return on equity of -89.54% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Summit Therapeutics	N/A	-168.94%	-141.92%

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Arcus Biosciences beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Arcus Biosciences (NYSE:RCUS) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Arcus Biosciences has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Arcus Biosciences presently has a consensus target price of $38.30, suggesting a potential upside of 55.54%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 35.77%. Given Arcus Biosciences' higher possible upside, research analysts plainly believe Arcus Biosciences is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Arcus Biosciences. MarketBeat recorded 21 mentions for BioMarin Pharmaceutical and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.05 beat BioMarin Pharmaceutical's score of 0.79 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	8 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a net margin of 2.14% compared to Arcus Biosciences' net margin of -393.16%. BioMarin Pharmaceutical's return on equity of 5.32% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.69	-$353M	-$3.90	N/A
BioMarin Pharmaceutical	$3.22B	3.95	$348.90M	$0.37	177.51

Summary

BioMarin Pharmaceutical beats Arcus Biosciences on 12 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Halozyme Therapeutics has a net margin of 24.86% compared to Arcus Biosciences' net margin of -393.16%. Halozyme Therapeutics' return on equity of 260.98% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Halozyme Therapeutics presently has a consensus price target of $91.20, suggesting a potential downside of 14.93%. Arcus Biosciences has a consensus price target of $38.30, suggesting a potential upside of 55.54%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Halozyme Therapeutics has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00
Arcus Biosciences	$247M	12.69	-$353M	-$3.90	N/A

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

In the previous week, Halozyme Therapeutics had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.05 beat Halozyme Therapeutics' score of 1.02 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats Arcus Biosciences on 10 of the 14 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCUS vs. The Competition

Export

Metric	Arcus Biosciences	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$3.33B	$3.84B	$7.13B	$23.17B
Dividend Yield	N/A	3.63%	2.56%	3.56%
P/E Ratio	-6.31	14.25	275.24	28.71
Price / Sales	12.69	1,473.06	655.99	94.44
Price / Cash	N/A	106.68	77.04	33.82
Price / Book	4.22	15.12	10.33	4.74
Net Income	-$353M	-$22.86M	$3.50B	$1.07B
7 Day Performance	-17.01%	-4.34%	-3.32%	-2.00%
1 Month Performance	-14.74%	-0.02%	-0.41%	-2.69%
1 Year Performance	114.12%	40.64%	19.21%	10.45%

Arcus Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCUS Arcus Biosciences	3.4234 of 5 stars	$24.62 -5.8%	$38.30 +55.5%	+114.0%	$3.33B	$247M	N/A	601	Positive News Analyst Forecast High Trading Volume
BBIO BridgeBio Pharma	3.4571 of 5 stars	$74.84 flat	$101.53 +35.7%	+37.7%	$14.63B	$502.08M	N/A	400	Analyst Forecast
EXEL Exelixis	2.4691 of 5 stars	$59.01 flat	$50.07 -15.2%	+43.6%	$14.62B	$2.32B	18.56	1,077	Trending News Analyst Forecast
SMMT Summit Therapeutics	3.6754 of 5 stars	$17.60 flat	$24.07 +36.8%	-5.6%	$14.04B	N/A	N/A	110	Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.6227 of 5 stars	$66.53 flat	$89.17 +34.0%	+17.5%	$12.88B	$3.22B	179.81	3,221	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RCUS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Competitors

RCUS vs. BBIO, EXEL, SMMT, BMRN, and HALO

How does Arcus Biosciences compare to BridgeBio Pharma?

Summary

How does Arcus Biosciences compare to Exelixis?

Summary

How does Arcus Biosciences compare to Summit Therapeutics?

Summary

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Summary

How does Arcus Biosciences compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Competitors

RCUS vs. BBIO, EXEL, SMMT, BMRN, and HALO

How does Arcus Biosciences compare to BridgeBio Pharma?

Does the media prefer RCUS or BBIO?

Do analysts rate RCUS or BBIO?

Do institutionals and insiders hold more shares of RCUS or BBIO?

Which has more risk & volatility, RCUS or BBIO?

Is RCUS or BBIO more profitable?

Which has higher valuation & earnings, RCUS or BBIO?

Summary

How does Arcus Biosciences compare to Exelixis?

Do analysts rate EXEL or RCUS?

Do insiders & institutionals hold more shares of EXEL or RCUS?

Which has better valuation and earnings, EXEL or RCUS?

Is EXEL or RCUS more profitable?

Does the media favor EXEL or RCUS?

Which has more volatility and risk, EXEL or RCUS?

Summary

How does Arcus Biosciences compare to Summit Therapeutics?

Which has stronger earnings and valuation, RCUS or SMMT?

Do analysts rate RCUS or SMMT?

Does the media refer more to RCUS or SMMT?

Which has more risk and volatility, RCUS or SMMT?

Is RCUS or SMMT more profitable?

Do institutionals & insiders have more ownership in RCUS or SMMT?

Summary

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Which has more volatility and risk, RCUS or BMRN?

Do analysts prefer RCUS or BMRN?

Do insiders and institutionals hold more shares of RCUS or BMRN?

Does the media favor RCUS or BMRN?

Is RCUS or BMRN more profitable?

Which has better valuation and earnings, RCUS or BMRN?

Summary

How does Arcus Biosciences compare to Halozyme Therapeutics?

Is HALO or RCUS more profitable?

Do analysts prefer HALO or RCUS?

Which has stronger earnings & valuation, HALO or RCUS?

Do insiders & institutionals hold more shares of HALO or RCUS?

Which has more risk & volatility, HALO or RCUS?

Does the media prefer HALO or RCUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools